Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoStart with Pro — $79/mo
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Financial ResultsItem 2.02 · 8-KLOW RiskNeutral

Pyxis Oncology, Inc.

Filed: Mar 23, 2026CIK: 0001782223
View on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Pyxis Oncology announced its full year 2025 financial results on March 23, 2026, providing stakeholders with performance metrics and strategic updates that are critical for evaluating the company's financial health and operational direction.

Key Takeaways

Company released full year 2025 financial results with detailed performance metrics showing significant changes compared to prior periods

Corporate update outlined strategic initiatives and upcoming projects that may influence investor perception and market positioning

2 more takeaways

Filing Overview

Form Type8-K
Filing DateMar 23, 2026
Item2.02
CategoryFinancial Results
CIK0001782223
Accession #0001782223
Risk LevelLOW
SentimentNeutral
Signalinformational
Topics
earningsguidance update

What This Means

The company is reporting financial results. Look for revenue trends, profitability changes, and forward guidance.
View Full Filing on SEC.govBrowse More Filings